We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

58 hedge funds and large institutions have $551M invested in Aimmune Therapeutics in 2015 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
58
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
2
FCMI
Foresite Capital Management II
California
+$95.6M
3
AC
Aisling Capital
New York
+$65.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$29M
5
PHS
PFM Health Sciences
California
+$23.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$1.27M +$1.17M +50,000 New
Federated Hermes
27
Federated Hermes
Pennsylvania
$1.27M +$1.17M +50,000 New
LCM
28
Landscape Capital Management
New Jersey
$1.21M +$1.12M +47,700 New
MOACM
29
Mutual of America Capital Management
New York
$1.06M +$980K +41,900 New
EA
30
Emerald Advisers
Pennsylvania
$1.04M +$962K +41,140 New
EMFAT
31
Emerald Mutual Fund Advisers Trust
Pennsylvania
$1.02M +$942K +40,280 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$972K +$897K +38,373 New
BIM
33
BlackRock Investment Management
Delaware
$939K +$867K +37,101 New
TCIM
34
TIAA CREF Investment Management
New York
$850K +$785K +33,579 New
Northern Trust
35
Northern Trust
Illinois
$809K +$747K +31,958 New
Bank of New York Mellon
36
Bank of New York Mellon
New York
$667K +$616K +26,343 New
PIM
37
Partner Investment Management
California
$577K +$533K +22,796 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$514K +$475K +20,300 New
Goldman Sachs
39
Goldman Sachs
New York
$392K +$362K +15,482 New
TA
40
Teachers Advisors
New York
$286K +$264K +11,294 New
EEG
41
E.E. Geduld
$258K +$238K +10,200 New
Charles Schwab
42
Charles Schwab
California
$256K +$235K +10,072 New
Jane Street
43
Jane Street
New York
$252K +$232K +9,943 New
Bank of America
44
Bank of America
North Carolina
$218K +$202K +8,619 New
BA
45
BlackRock Advisors
Delaware
$134K +$124K +5,292 New
TRCT
46
Tower Research Capital (TRC)
New York
$100K +$92.7K +3,964 New
SO
47
STRS Ohio
Ohio
$91K +$84.2K +3,600 New
Deutsche Bank
48
Deutsche Bank
Germany
$77K +$71.9K +3,074 New
Wells Fargo
49
Wells Fargo
California
$71K +$66.4K +2,839 New
NFA
50
Nationwide Fund Advisors
Ohio
$69K +$63.8K +2,730 New
1
2
3

AIMT Hedge Fund Activity: Q3 2015 in Review

58 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2015, worth a combined $551M.

Buyers outnumbered sellers: 58 funds opened new AIMT positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $142M.

  • 58 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2015, up from 0 in Q2 2015.
  • Funds reported $551M of Aimmune Therapeutics stock for Q3 2015.
  • 58 funds opened new Aimmune Therapeutics positions in Q3 2015 and 0 closed out, a net change of +58 holders.
  • The largest Aimmune Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $142M added.

Based on aggregated 13F filings for Q3 2015.